Literature DB >> 12660452

Significance of protein p53 overexpression in the clinical course of high-risk superficial bladder cancer.

P Gil1, C Allepuz, M Blas, A Borque, C del Agua, L Plaza, L A Rioja.   

Abstract

OBJECTIVES: This is a retrospective study in which the long-term biological behavior of 67 "high-risk" superficial bladder tumors and the prognostic relevance (prediction of disease recurrence and progression) of the determination of the p53 phenotype in these cases were studied.
MATERIAL AND METHODS: 67 tumors with a "high-risk" of progression were selected from the 1,103 transurethral resections for bladder cancer carried out in 640 patients in this center between 1987 and 1992. These included 39 T1G3, 14 Tis (isolated or associated with Ta-T1, non-G3 tumors), and 14 Ta-T1, non-G3 tumors with submucosal lymphatic affection (L+). The median follow-up of these cases was 69.7 months. An immunohistochemical technique with monoclonal antibodies (DO-7) was used to detect the p53 phenotype in paraffin-fixed material.
RESULTS: Tumor recurrence occurred in 31 patients (46.3%) and local or distant progression in 14 (20.9%). Radical cystectomy was carried out in 16 (23.9%) cases. p53 overexpression of > or =20% ("p53+") was detected in 40 tumors (59.7%). The rate of recurrence and progression, the disease and progression-free intervals, cancer-specific survival, disease-free survival and progression-free survival were similar in the 3 tumor groups (in all cases, p > 0.05). There were no significant differences in the overexpression of protein p53, using the standard cutoff point of 20% stained nuclei, on comparing the same variables in the whole group of 67 patients (in all cases, p > 0.05).
CONCLUSION: The detection of protein p53 was not found to be of use in the retrospective prediction of disease progression or survival in "high-risk" superficial bladder cancer. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660452     DOI: 10.1159/000068774

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  3 in total

1.  Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer.

Authors:  Farha A El-Chennawi; Fatma A Auf; Shereen S Metwally; Youssef M Mosaad; Atallah A Shaaban; Mahmoud Abdo El-Baz; Ziyad E Tawhid; Zakaria F Lotfy
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

2.  Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

Authors:  Malte W Vetterlein; Julia Roschinski; Philipp Gild; Phillip Marks; Armin Soave; Ousman Doh; Hendrik Isbarn; Wolfgang Höppner; Walter Wagner; Shahrokh F Shariat; Maurizio Brausi; Franziska Büscheck; Guido Sauter; Margit Fisch; Michael Rink
Journal:  Transl Androl Urol       Date:  2017-12

3.  p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.

Authors:  Jun Du; Shu-hua Wang; Qing Yang; Qian-qian Chen; Xin Yao
Journal:  World J Surg Oncol       Date:  2016-04-30       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.